Member Info for CanaryDwarf

I thought that 5% was on the low side. Which means that either the tests being used aren’t picking up antibodies or not everybody who contracts Covid produces antibodies. Sounds a bit hit or miss from a testing point of view..

Spain's large-scale study (61k people) indicates just 5% of its population has developed coronavirus antibodies - ie herd immunity “unachieveable” without vaccines. Largest antibody study in Europe according to European CDC

More skin in the game through their options

No surprise to move back to 15p support. Now hopefully new 2020 highs

Simec Atlantic’s website..
https://simecatlantis.com/2020/05/29/4291/

The Uskmouth conversion project pre application consultation completes on Monday. Is this significant news that might impact the SP?

Showing some real strength after some earlier profit taking. Still surprised how low this market cap is.

Nice article highlighting some very exciting projects. Looking forward to hearing about the test results from Nagasaki- can’t be long now

Is the price being dragged down from bad press re: biomas powerplants? Which is Completely unrelated to SAE..

Any interviews/podcasts scheduled today? May help..

Any more news regarding Belluscura joining AIM? Should provide a significant re-rate of TEK when details start emerging IMO..still very much under the radar

So undervalued IMO..

I wonder if TechRunway will provide funding as part of their program?

Agreed. Guident is the dark horse of the portfolio currently with the largest valuation.

Don’t forget TEK is trading at a 50%+ discount to Net Asset Value, based upon the valuation provided in the 2019 full year results. I would have thought that the NAV would be considerable higher with FDA approval for Belluscura and roll out of SaltMe products.. IMO, this will be trading in the 30p+ range very soon..

90 business day after 4th Feb takes us to 11thJune. So FDA approval any day between now and then.. a re- rate should follow on FDA approval.. as the fair value of the Belluscura portfolio will rise significantly..

Full year results out soon? Can’t wait sit to read the independent fair value of the portfolio.

What a great time to get FDA approval for a market leading product! This company is so undervalued IMO.

https://www.businesswire.com/news/home/20200501005439/en/

Portable Oxygen Concentrators are needed to address the respiratory difficulties brought by COVID-19. Portable Oxygen Concentrators are but one aspect of the ways that Boards of Health have to approach the pandemic, but an essential aspect.

To stop COVID-19 extensive testing is needed, in combination with the use of Portable Oxygen Concentrators, hand sanitizer continued to shelter in place, and selected quarantine response.

The worldwide market for Portable Oxygen Concentrators, at $1 billion in 2019, will grow to $3 billion by 2026. The unmistakable impact of disease in increasing the death rates worldwide is driving people to take advantage of home oxygen relief.

‘ Because the device Belluscura is working on helps distill air into 96% oxygen and help patients who are having trouble breathing – some of the most severe symptoms of COVID-19 – it has received designation as an Emergency Use Authorized Product by the FDA, meaning its approval can be expedited’

https://www.americaninno.com/northtexas/news-northtexas/plano-medical-device-startup-donates-face-masks-to-those-at-risk/

I can see a huge market for these types of smart glasses once AR takes off. I assume Lucyd are moving into AR, if not already? Very cool..